This placebo-controlled, randomised trial (n=90) investigates the efficacy of a single infusion of ketamine combined with magnesium sulphate in treating refractory chronic cluster headache (CCH).
Status: Recruiting
Start date: 2021-09-15
Phase IV
Blinded
88 participants
Interventional
This randomised, double-blind clinical trial (n=0, terminated) aimed to compare the effectiveness of ketamine (21mg/70kg) to prochlorperazine (Compazine) in treating benign headaches in the Emergency Department.
Status: Terminated
Start date: 2016-08-01
Phase III
Blinded
5 participants
Interventional
This prospective, randomised, open-label trial (n=5) compared the analgesic efficacy and safety of a proprietary formulation of orally administered aspirin and ketamine (AOK) to Nurtec (Rimegepant) in adult patients presenting to the Emergency Department (ED) with acute headache.
Status: Completed
Start date: 2021-04-22
Phase IV
Open
5 participants
Interventional
This open-label trial (n=20) conducted in Denmark by CCH Pharmaceuticals, with the protocol code CCH01, aimed to assess the efficacy of ketamine intranasal spray in treating chronic Cluster Headache (CCH)
Status: Completed
Start date: 2019-08-16
Phase II
Open
20 participants
Interventional
This double-blind, placebo-controlled trial (n=65) will assess the efficacy and safety of LSD (25μg) every 3 days for 3 weeks versus placebo in treating chronic cluster headaches (CCH).
Status: Not yet recruiting
Start date: 2024-01-01
Phase II
Blinded
64 participants
Interventional
This placebo-controlled trial (n=56) will investigate the efficacy and safety of high-dose intravenous ketamine infusion in treating Chronic Daily Headaches (CDH) syndrome.
Status: Recruiting
Start date: 2022-06-01
Phase III
Blinded
56 participants
Interventional
This double-blind cross-over trial (n=24) investigates the effect of repeated doses of psilocybin (2x) at varying doses of psilocybin (1 or 10mg) on concussion headache.
Status: Recruiting
Start date: 2019-03-28
Phase I
Blinded
24 participants
Interventional
This double-blind, randomised study (n=65) will investigate if every third-day mini-dosing (25μg) of LSD for three weeks (7x dosing) alleviates chronic cluster headaches (CCH).
Status: Not yet recruiting
Start date: 2023-05-01
Phase II
Blinded
65 participants
Interventional
This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
Status: Terminated
Start date: 2021-5-21
Phase I
Open
12 participants
Interventional
This study aims to investigate the prophylactic effects of psilocybin in chronic cluster headaches. Subjects will receive a low dose of psilocybin during three sessions spaced over one week. Subjects will maintain a headache diary prior to, during, and after the administrations to document headache frequency, intensity and duration. Subjects will undergo an fMRI scanning before the first and after the last psilocybin session.
Status: Terminated
Start date: 2020-1-21
Phase I
Open
10 participants
Interventional
In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses.
Status: Not yet recruiting
Start date: 2021-7-15
Phase I
Blinded
24 participants
Interventional
After no official human research in the last 40 years, research and therapeutic uses of the serotonergic psychedelic lysergic acid diethylamide (LSD) are now re-recognized and include its use in brain research, alcoholism, anxiety associated with a terminal illness, and treatment of headache disorders. Specifically, LSD has been reported to abort attacks, decrease the frequency and intensity of attacks, and induce remission in patients suffering from cluster headaches (CH).
Status: Recruiting
Start date: 2019-01-02
Phase II
Blinded
30 participants
Interventional
The purpose of this study is to investigate the effects of oral psilocybin in migraine headache.
Status: Completed
Start date: 2017-1-11
Phase I
Blinded
24 participants
Interventional
The purpose of this study is to investigate the effects of an oral psilocybin pulse regimen in cluster headache. Subjects will be randomized to receive oral placebo, low dose psilocybin, or high dose psilocybin in three experimental sessions, each separated by 5 days.
Status: Completed
Start date: 2016-11-1
Phase I
Blinded
24 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
?>